We are live on
!
Find out more
UOC
UBS O'Connor Portfolio holdings
AUM
$3.76B
1-Year Est. Return
62.41%
This Fund
S&P 500
This Quarter
Est. Return
+0.05%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$3.55B
AUM Growth
+$59.4M
(+1.7%)
Cap. Flow
-$31.8M
Cap. Flow
% of AUM
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
49.57%
Holding
665
New
156
Increased
155
Reduced
111
Closed
128
Avg Time Held Equity + Options
3.9
quarters
Top 10 Avg Time Held Equity + Options
0.8
quarters
Top 20 Avg Time Held Equity + Options
1.2
quarters
Avg Time Held Equity only
4.3
quarters
Top 10 Avg Time Held Equity only
0.8
quarters
Top 20 Avg Time Held Equity only
1.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HashiCorp, Inc. Class A Common Stock
HCP
|
+$138M |
| 2 |
Equitrans Midstream Corporation Common Stock
ETRN
|
+$131M |
| 3 |
Endeavor Group Holdings, Inc.
EDR
|
+$127M |
| 4 |
Marathon Oil Corporation
MRO
|
+$123M |
| 5 |
ChampionX
CHX
|
+$98.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pioneer Natural Resource Co.
PXD
|
+$638M |
| 2 |
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$51.2M |
| 3 |
Discover Financial Services
DFS
|
+$45.1M |
| 4 |
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
|
+$18.4M |
| 5 |
Norfolk Southern
NSC
|
+$17.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 26.53% |
| 2 | Technology | 21.03% |
| 3 | Healthcare | 14.68% |
| 4 | Industrials | 8.19% |
| 5 | Miscellaneous | 6.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
426
PUT
Sinclair Inc
SBGI
$905M
| $79.3K | ﹤0.01% |
+109,400
| New | +$1.4M |
2024 Q2
0 quarters
|
|
427
PUT
UGI
UGI
$8.04B
| $73.5K | ﹤0.01% |
+71,700
| New | +$1.74M |
2024 Q2
0 quarters
|
|
428
PUT
Uber
UBER
$145B
| $71.3K | ﹤0.01% |
19,000
-151,000
| -89% | -$10.5M |
2023 Q4
2 quarters
|
|
429
PUT
Expedia Group
EXPE
$32.4B
| $67.6K | ﹤0.01% |
13,000
| – | – |
2022 Q2
8 quarters
|
|
430
PUT
Tanger
SKT
$4.04B
| $65.3K | ﹤0.01% |
+24,200
| New | +$666K |
2024 Q2
0 quarters
|
|
431
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
| $64.2K | ﹤0.01% |
60,000
-240,000
| -80% | -$21.5M |
2023 Q3
3 quarters
|
|
432
PUT
Vera Therapeutics
VERA
$2.04B
| $58.5K | ﹤0.01% |
30,000
+10,000
| +50% | +$397K |
2024 Q1
1 quarter
|
|
433
CALL
TG Therapeutics
TGTX
$8.4B
| $57.8K | ﹤0.01% |
70,000
-50,000
| -42% | -$798K |
2023 Q4
2 quarters
|
|
434
PUT
Danaher
DHR
$154B
| $54.5K | ﹤0.01% |
+10,000
| New | +$2.53M |
2024 Q2
0 quarters
|
|
435
PUT
DELISTED
Blueprint Medicines
BPMC
| $51K | ﹤0.01% |
+20,000
| New | +$2M |
2024 Q2
0 quarters
|
|
436
PUT
DELISTED
Tri Pointe Homes
TPH
| $50.6K | ﹤0.01% |
+24,700
| New | +$930K |
2024 Q2
0 quarters
|
|
437
DELISTED
Churchill Capital Corp VII Warrants
CVIIW
| $47.4K | ﹤0.01% |
133,530
| – | – |
2021 Q2
12 quarters
|
|
438
CALL
Axsome Therapeutics
AXSM
$8.77B
| $46.9K | ﹤0.01% |
+15,000
| New | +$1.11M |
2024 Q2
0 quarters
|
|
439
PUT
EPR Properties
EPR
$4.2B
| $46.3K | ﹤0.01% |
+25,700
| New | +$1.06M |
2024 Q2
0 quarters
|
|
440
CALL
Alnylam Pharmaceuticals
ALNY
$30.7B
| $46K | ﹤0.01% |
+10,000
| New | +$1.58M |
2024 Q2
0 quarters
|
|
441
PUT
XPLR Infrastructure LP
XIFR
$973M
| $42.7K | ﹤0.01% |
27,100
| – | – |
2023 Q3
3 quarters
|
|
442
PUT
Graphic Packaging
GPK
$2.44B
| $42.4K | ﹤0.01% |
+30,800
| New | +$851K |
2024 Q2
0 quarters
|
|
443
CALL
Sarepta Therapeutics
SRPT
$1.86B
| $40.5K | ﹤0.01% |
15,000
-20,000
| -57% | -$2.57M |
2024 Q1
1 quarter
|
|
444
DELISTED
Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share
CLBR.WS
| $38.7K | ﹤0.01% |
133,333
| – | – |
2024 Q1
1 quarter
|
|
445
DELISTED
Learn CW Investment Corporation Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
LCW.WS
| $38.4K | ﹤0.01% |
231,102
| – | – |
2023 Q4
2 quarters
|
|
446
PUT
Ardelyx
ARDX
$834M
| $37.5K | ﹤0.01% |
+100,000
| New | +$703K |
2024 Q2
0 quarters
|
|
447
CALL
Black Diamond Therapeutics
BDTX
$103M
| $37.1K | ﹤0.01% |
+46,400
| New | +$249K |
2024 Q2
0 quarters
|
|
448
CALL
Ultragenyx Pharmaceutical
RARE
$1.51B
| $37K | ﹤0.01% |
40,000
+29,300
| +274% | +$1.25M |
2023 Q2
4 quarters
|
|
449
CALL
DELISTED
Merus
MRUS
| $36.8K | ﹤0.01% |
15,000
-5,000
| -25% | -$242K |
2024 Q1
1 quarter
|
|
450
PUT
Vaxcyte
PCVX
$10.9B
| $36.5K | ﹤0.01% |
+10,000
| New | +$681K |
2024 Q2
0 quarters
|
|
Similar funds
FNBT
ACI
RC
A
CGL
CB
JCM
MPM
UBS O'Connor's Q2 2024 Portfolio in Review
As of Q2 2024, UBS O'Connor held 665 positions worth $3.55B, up 1.7% from $3.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
UBS O'Connor's Q2 2024 filing shows 156 new, 155 increased, 111 reduced and 128 closed positions. Its largest new stake was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M. The largest sale was Pioneer Natural Resource Co., an estimated $638M.
By sector, the portfolio is most concentrated in Energy at 27% of assets, down from 34% a quarter earlier, followed by Technology and Healthcare.
- UBS O'Connor's largest Q2 2024 buy was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M.
- UBS O'Connor added most to HashiCorp, Inc. Class A Common Stock in Q2 2024, an estimated $138M increase.
- UBS O'Connor's biggest Q2 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $51.2M.
- UBS O'Connor fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $638M.
- UBS O'Connor's ten largest holdings make up 50% of its $3.55B portfolio in Q2 2024.
- UBS O'Connor opened 156 new positions and closed 128 in Q2 2024.
- UBS O'Connor's portfolio value rose 1.7% quarter-over-quarter to $3.55B.
Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.